Matches in SemOpenAlex for { <https://semopenalex.org/work/W2404591430> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2404591430 endingPage "809" @default.
- W2404591430 startingPage "789" @default.
- W2404591430 abstract "With the arrival of progestin therapy for advanced, metastatic and recurrent endometrial cancer a quarter of a century ago, came the discovery that approximately one-third of all these tumors would show a clinical response. Probably no more than half of this group will survive more than 5 years. Identification of the type of patient who is most likely to respond has proven difficult. Both clinical and histopathological characteristics act only as an unreliable guide. The site of metastasis and the time for a recurrence to appear are the most constant of these factors. It is hoped that the steroid receptor content of the tumor will prove to be as valuable as it has been in the case of breast cancer. At the moment this is under investigation with numerous ongoing studies. Type, dosage and mode of administration of progestin do not appear to be critical factors in tumor response, nor does the type of synthetic agent used. However, medroxyprogesterone has been the subject of numerous symposia and is the best researched. It also offers the opportunity of being administered orally and in large doses. All agents are virtually free of toxic effects and cessation on this basis is unusual. For patients with tumors that either do not respond to progestin, or else have a temporary response, other agents--antiestrogens and cytotoxic--may well prove to be of value either simultaneously or sequentially. These possibilities are under current investigation. The definitive therapy of primary 'nonadvanced' disease is not established and is at this point unproven in any significant published randomized study. Orthodox proven methods of treatment, i.e. surgery and irradiation, must form the initial component in every patient's therapy, whatever the stage of the disease. It is hoped that prospective studies will elucidate the place of progestins in an adjunctive primary setting. However, it must be emphasized that such studies must concentrate on 'high-risk' patients. The probability of proof in any group of 'good prognosis' patients--whatever the numbers entered--appears to be very low." @default.
- W2404591430 created "2016-06-24" @default.
- W2404591430 creator A5033383802 @default.
- W2404591430 date "1986-12-01" @default.
- W2404591430 modified "2023-09-23" @default.
- W2404591430 title "Adjunctive and therapeutic progestins in endometrial cancer." @default.
- W2404591430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3641697" @default.
- W2404591430 hasPublicationYear "1986" @default.
- W2404591430 type Work @default.
- W2404591430 sameAs 2404591430 @default.
- W2404591430 citedByCount "5" @default.
- W2404591430 crossrefType "journal-article" @default.
- W2404591430 hasAuthorship W2404591430A5033383802 @default.
- W2404591430 hasConcept C121608353 @default.
- W2404591430 hasConcept C126322002 @default.
- W2404591430 hasConcept C143998085 @default.
- W2404591430 hasConcept C2775930923 @default.
- W2404591430 hasConcept C2775934596 @default.
- W2404591430 hasConcept C2776306185 @default.
- W2404591430 hasConcept C2776607906 @default.
- W2404591430 hasConcept C2777088508 @default.
- W2404591430 hasConcept C2779134260 @default.
- W2404591430 hasConcept C530470458 @default.
- W2404591430 hasConcept C71315377 @default.
- W2404591430 hasConcept C71924100 @default.
- W2404591430 hasConceptScore W2404591430C121608353 @default.
- W2404591430 hasConceptScore W2404591430C126322002 @default.
- W2404591430 hasConceptScore W2404591430C143998085 @default.
- W2404591430 hasConceptScore W2404591430C2775930923 @default.
- W2404591430 hasConceptScore W2404591430C2775934596 @default.
- W2404591430 hasConceptScore W2404591430C2776306185 @default.
- W2404591430 hasConceptScore W2404591430C2776607906 @default.
- W2404591430 hasConceptScore W2404591430C2777088508 @default.
- W2404591430 hasConceptScore W2404591430C2779134260 @default.
- W2404591430 hasConceptScore W2404591430C530470458 @default.
- W2404591430 hasConceptScore W2404591430C71315377 @default.
- W2404591430 hasConceptScore W2404591430C71924100 @default.
- W2404591430 hasIssue "4" @default.
- W2404591430 hasLocation W24045914301 @default.
- W2404591430 hasOpenAccess W2404591430 @default.
- W2404591430 hasPrimaryLocation W24045914301 @default.
- W2404591430 hasRelatedWork W1561411784 @default.
- W2404591430 hasRelatedWork W1971193337 @default.
- W2404591430 hasRelatedWork W1975188266 @default.
- W2404591430 hasRelatedWork W1980959075 @default.
- W2404591430 hasRelatedWork W2041658447 @default.
- W2404591430 hasRelatedWork W2071021042 @default.
- W2404591430 hasRelatedWork W2083030277 @default.
- W2404591430 hasRelatedWork W2157464927 @default.
- W2404591430 hasRelatedWork W2279210530 @default.
- W2404591430 hasRelatedWork W2404591430 @default.
- W2404591430 hasVolume "13" @default.
- W2404591430 isParatext "false" @default.
- W2404591430 isRetracted "false" @default.
- W2404591430 magId "2404591430" @default.
- W2404591430 workType "article" @default.